Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock

Published 10/06/2025, 20:18
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock

On June 9, 2025, Joshua R. Disbrow, the Chief Executive Officer of Aytu BioPharma, Inc. (NASDAQ:AYTU), purchased a significant amount of the company’s common stock. According to a recent SEC filing, Disbrow acquired 66,666 shares at a price of $1.50 per share, totaling $99,999. The stock has since rallied to $2.10, delivering a remarkable 36% return in the past week. InvestingPro analysis indicates the company is currently trading at an attractive revenue multiple. This transaction was conducted as part of Aytu BioPharma’s registered offering, as outlined in the company’s Registration Statement on Form S-1 filed earlier this month. Following this acquisition, Disbrow’s direct ownership in Aytu BioPharma increased to 153,257 shares. While the company wasn’t profitable in the last twelve months, InvestingPro data shows analysts expect profitability this year. Discover more insights about AYTU and track insider trading patterns with InvestingPro’s comprehensive research reports, available for 1,400+ US stocks.

In other recent news, Aytu BioPharma reported a strong financial performance in the third quarter of fiscal year 2025. The company achieved a 32% increase in net revenue year-over-year, reaching $18.5 million, which was driven by significant growth in its ADHD and pediatric portfolios. Aytu BioPharma also reported a net income of $4 million, marking a turnaround from a loss in the prior year, and achieved an adjusted EBITDA of $3.9 million. The company’s ADHD portfolio generated $15.4 million in revenue, up 25% from the previous year, while the pediatric portfolio saw a 77% increase, contributing $3.1 million to the total revenue. Additionally, Aytu BioPharma has secured exclusive rights to commercialize EXXUA™, a new FDA-approved antidepressant for major depressive disorder, in the U.S. market. The company plans to launch EXXUA in the fourth quarter of 2025, with strong financial backing from Nantahala Capital Management and other institutional investors. The financial terms of the agreement with Fabre-Kramer Pharmaceuticals include upfront payments, royalties, and performance-based milestone payments. Aytu BioPharma is also exploring strategic acquisitions to complement its existing product lines, particularly in the CNS and pediatric therapeutic areas.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.